Drug intelligence / Profile preview

IBI-129

Development stage: Phase 2
Lead developer: Innovent Biologics
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

IBI-129 is an antibody-drug conjugate (ADC) under development by Innovent Biologics for the treatment of solid tumors, including prostate cancer and small cell lung cancer. The drug targets cells expressing the CD276 antigen, also known as B7 homolog 3 (B7-H3), a protein frequently overexpressed in various tumor types. By binding to CD276, IBI-129 delivers a cytotoxic payload directly to tumor cells, aiming to enhance antitumor efficacy while minimizing off-target toxicity. The drug is administered intravenously as a powder formulation and is currently in Phase II clinical trials for solid tumors.

Targets

B7-H3

Beyond the preview

Go deeper on IBI-129.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IBI-129.

Explore the full profile